Did you know?

For many patients with difficult-to-treat cancers, the options have been few. Verastem Oncology aims to change that by pursuing RAS pathway-targeted treatment combinations with avutometinib (VS-6766). Find out more about our clinical trials here. FIND A TRIAL. Verastem-Sponsored Trials Investigator-Sponsored Trials.Verastem press release (VSTM): Q1 Non-GAAP EPS of -$0.09.Verastem Oncology ended the first quarter of 2023 with cash, cash equivalents and investments of $111.2 million.Shares -4% AH.Latest FSRN News. No FSRN news at the moment. Track Fisker Inc (FSRN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.Shares of NASDAQ VSTM opened at $12.02 on Monday. The firm's 50-day moving average price is $11.13 and its 200-day moving average price is $9.93. Verastem has a 1-year low of $4.68 and a 1-year ...On the other hand, Verastem plummeted 65% after its latest pancreatic cancer clinical trial safety data disappointed. 💉 . Electric vehicle maker Lucid Group is cutting its U.S. workforce by 6% (400 employees) as it grapples with the slower-growth environments. The cuts will impact all levels but not hourly manufacturing and logistics workers ...China's one-child policy may not have been necessary. Learn what would happen if China never had a one-child policy at HowStuffWorks. Advertisement Back in 1979, China was dealing ...May. 25, 2023, 09:05 PM. In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Hold rating on Verastem ( VSTM - Research Report ), with a price target of $2.00. The ...Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019–)Verastem Oncology (Verastem Inc) is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts , the firm is a member of NASDAQ Biotechnology Index .Shares of Verastem, Inc. (NASDAQ:VSTM - Get Free Report) have been assigned an average recommendation of "Buy" from the six brokerages that are covering the firm, Marketbeat.com reports.Six investment analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $28.79.Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019-)Interactive stock price chart for Verastem, Inc. (VSTM) with real-time updates, full price history, technical analysis and more.BOSTON, June 16, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten ...Verastem Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Verastem Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.974 per share for the current fiscal year.Price to Book. 11.61. Revenue Per Employee. N/A. Enterprise Value/EBITDA. -2.77. Get all financial information for Verastem Inc (VSTM) including Market Capitalization, PE Ratio, EBITDA, EPS, previous close and open price, 52 week high & 52 week low, Beta and much more.Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!Verastem Oncology has initiated Phase 2 registration-directed trials evaluating the combination of VS-6766 alone and with defactinib in patients with recurrent LGSOC and in patients with recurrent KRAS-G12V mutant NSCLC as part of its RAMP (Raf And Mek Program). RAMP 201 (ENGOTov60/GOG3052) is an adaptive, two-part …BBG001J2LSK5. Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered ...Verastem Inc News Alert. Email. Leave this field blank. Investor Contact. Julissa Viana. Investor Relations [email protected]. Ryan Porter. Argot Partners +1 212-600-1902 [email protected]. Investor Kit Corporate Presentation 1.8 MB. VSTM-Form-10-K-2023.pdf 1.7 MB.Aqua Metals, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: AQMS | NasdaqTrack VESTIS CORPORATION (VSTS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsBOSTON--(BUSINESS WIRE)--Jan. 18, 2023-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of 96,700 restricted stock units (RSUs) to four new employees.The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees' acceptance of ...Verastem saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 825,400 shares, an increase of 2.4% from the previous total of 806,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price ...Analysts Offer Insights on Healthcare CompanBOSTON, January 18, 2024--Verastem Oncology (Nasdaq:VSTM), a b Oct 14, 2023 · The forward-looking statements contained in this press release reflect Verastem Oncology’s views as of the date hereof, and Verastem Oncology does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. Find the latest Verastem, Inc. (VSTM) stock quo Based on 3 Wall Street analysts offering 12 month price targets for Verastem in the last 3 months. The average price target is $31.67 with a high forecast of $36.00 and a low forecast of $27.00. The average price target represents a 187.91% change from the last price of $11.00. Highest Price Target $36.00. Average Price Target $31.67. Track Vertical Aerospace Ltd (EVTL) Stock Pr

At Verastem Oncology, we’re working every day to make sure they don’t. By embracing the power of external partnerships and collaboration, we’re putting our collective knowledge and expertise to work to deliver novel treatment approaches that address areas of high unmet need in RAS pathway-driven cancers. Patients desperately need better ...Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition.Verastem recently publicized updated data from the Part A portion of their registration-directed RAMP 201 Phase II trial of Avutometinib "VS-6766" as a monotherapy or in combination with ...We would like to show you a description here but the site won’t allow us.

Credit: Kateryna Kon / Shutterstock.com. The US Food and Drug Administration (FDA) has granted fast track designation for Verastem Oncology's investigational therapy, avutometinib, for treating non-small cell lung cancer (NSCLC). The FDA designation is intended for the use of avutometinib along with Amgen 's LUMAKRAS (sotorasib) to treat ...Jan 27, 2012 · Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is ...…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Track Aeva Technologies Inc (AEVA) Stock Price, Quote, latest communi. Possible cause: Verastem Oncology | 13,729 followers on LinkedIn. Verastem Oncology (Nasdaq: .